Zacks Research Issues Negative Outlook for Azitra Earnings

Azitra, Inc. (NYSEAMERICAN:AZTR) – Investment analysts at Zacks Research decreased their Q3 2026 earnings per share estimates for shares of Azitra in a research note issued to investors on Monday, November 2nd. Zacks Research analyst J. Vandermosten now anticipates that the company will post earnings of ($0.25) per share for the quarter, down from their previous estimate of ($0.20). The consensus estimate for Azitra’s current full-year earnings is ($2.05) per share. Zacks Research also issued estimates for Azitra’s Q4 2026 earnings at ($0.25) EPS, FY2026 earnings at ($2.05) EPS, FY2027 earnings at ($0.64) EPS and FY2028 earnings at ($0.61) EPS.

Azitra Trading Down 12.1%

Shares of AZTR opened at $0.64 on Monday. The stock has a 50 day moving average price of $1.79 and a 200 day moving average price of $1.89. Azitra has a one year low of $0.52 and a one year high of $4.30.

Azitra (NYSEAMERICAN:AZTR) last released its earnings results on Wednesday, August 12th. The company reported ($1.70) earnings per share for the quarter, missing the consensus estimate of ($1.15) by ($0.55).

Azitra Company Profile

Azitra, Inc is a clinical-stage biotechnology company focused on developing microbiome-based therapies for dermatological conditions. The company combines microbiology, genetic engineering and computational tools to identify and develop targeted treatments intended to address diseases affecting the skin.

Azitra’s platform centers on engineered strains of beneficial skin bacteria and biologic compounds designed to deliver therapeutic proteins or otherwise influence the skin’s local environment.